RegulatoryAug 6, 2026, 04:24 PM
Zhengye Biotechnology Regains Nasdaq Bid Price Compliance
AI Summary
Zhengye Biotechnology Holding Limited announced it has regained compliance with Nasdaq's minimum bid price requirement. The company previously received a notification on May 29, 2026, indicating its Class A ordinary shares had traded below $1.00 for 30 consecutive business days. After its shares traded at or above $1.00 for ten consecutive business days from July 20 to August 4, 2026, Nasdaq confirmed compliance on August 5, 2026, allowing the company to maintain its listing.
Key Highlights
- Received Nasdaq notification on May 29, 2026, for non-compliance with minimum bid price rule.
- Company's Class A ordinary shares were below $1.00 for 30 consecutive business days.
- Compliance period was set until November 25, 2026 (180 calendar days).
- Closing bid price was $1.00 or greater for 10 consecutive business days from July 20 to August 4, 2026.
- Received a letter from Nasdaq on August 5, 2026, confirming regained compliance.
- Zhengye Biotechnology remains listed on The Nasdaq Capital Market under ticker ZYBT.
Price Impact
More from ZYBT